NASDAQ: $JAZZ A Strategic Financial Move Jazz Pharmaceuticals has officially announced the pricing of an upsized private offering of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032. The company initially planned for a smaller offering but increased the size due to market demand, reflecting strong investor interest in the pharmaceutical leader’s…